GelSana, a 2025 MedTech Innovator company, is engineering smart polymer wound dressings that improve wound healing without drugs by reducing inflammation and repelling bacteria, and that are durable and conformable to a wide range of wounds. GelSana is heading to the clinical market with our first product Cleragel which will be registered with the FDA as a 510(k)-exempt medical device. GelSana has secured a total of $5.5M in funding to date, including $3M from investors and $2.5M from grants from NIH, Air Force, and State of Colorado.
The RVC Deep Dive is a 90 minute virtual meeting held between company executive leadership, RVC Investors, and RVC staff. The purpose of this meeting is to cover all major due diligence questions such as business strategy, team, product, competition, IP, market, traction, key risks, and exit strategy.
The structure of the meeting is as follows:
To attend, you must be an accredited investor (net worth of at least one million US dollars, not including the value of one’s primary residence, or have made at least $200,000 each year for the last two years [or $300,000 together with his or her spouse if married] and have the expectation to make the same amount this year). We do not require a minimum investment.